Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2030

Conditions
Clonal Cytopenia of Undetermined Significance
Interventions
DRUG

Ivosidenib

. Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.

Trial Locations (2)

44195

Cleveland Clinic - Case Comprehensive Cancer Center, Cleveland

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Servier Hellas Pharmaceuticals Ltd.

INDUSTRY

collaborator

Gateway for Cancer Research

OTHER

lead

Washington University School of Medicine

OTHER